The sodium-chloride symporter (also known as Na+-Cl− cotransporter, NCC or NCCT, or as the thiazide-sensitive Na+-Cl− cotransporter or TSC) is a
cotransporter in the
kidney which has the function of reabsorbing
sodium and
chlorideions from the
tubular fluid into the cells of the
distal convoluted tubule of the
nephron. It is a member of the
SLC12 cotransporter family of electroneutral cation-coupled chloride cotransporters. In humans, it is encoded by the SLC12A3gene (solute carrier family 12 member 3) located in
16q13.[5]
A loss of NCC function causes
Gitelman syndrome, an autosomic recessive disease characterized by salt wasting and low blood pressure, hypokalemic metabolic alkalosis, hypomagnesemia and hypocalciuria.[6] Over a hundred different mutations in the NCC gene have been identified.
N-glycosylation occurs in two sites in a long extracellular loop connecting two transmembrane domains within the hydrophobic core. This
posttranslational modification is necessary for proper folding and transport of the protein to the
plasma membrane.[7]
Function
Because NCC is located at the
apical membrane of the distal convoluted tubule of the nephron, it faces the
lumen of the tubule and is in contact with the tubular fluid. Using the
sodium gradient across the apical membrane of the cells in distal convoluted tubule, the sodium-chloride symporter transports Na+ and Cl− from the tubular fluid into these cells. Afterward, the Na+ is pumped out of the cell and into the bloodstream by the Na+-K+ ATPase located at the
basal membrane and the Cl− leaves the cells through the basolateral
chloride channel ClC-Kb. The sodium-chloride symporter accounts for the absorption of 5% of the salt filtered at the
glomerulus. NCC activity is known to have two control mechanisms affecting protein trafficking to the plasma membrane and transporter kinetics by
phosphorylation and de-phosphorylation of conserved serine/threonine residues.
As NCC has to be at the plasma membrane to function, its activity can be regulated by increasing or decreasing the amount of protein at the plasma membrane. Some NCC modulators, such as the
WNK3 and
WNK4 kinases may regulate the amount of NCC at the cell surface by inducing the insertion or removal, respectively, of the protein from the plasma membrane.[8][9]
Furthermore, many residues of NCC can be phosphorylated or dephosphorylated to activate or inhibit NCC uptake of Na+ and Cl−. Other NCC modulators, including intracellular chloride depletion,
angiotensin II,
aldosterone and
vasopressin, can regulate NCC activity by phosphorylating conserved serine/threonine residues.[10][11][12] NCC activity can be inhibited by
thiazides, which is why this symporter is also known as the thiazide-sensitive Na+-Cl− cotransporter.[5]
Pathology
Gitelman syndrome
A loss of NCC function is associated with
Gitelman syndrome, an autosomic recessive disease characterized by salt wasting and low blood pressure, hypokalemic metabolic alkalosis, hypomagnesemia and hypocalciuria.[6]
Over a hundred different mutations in the NCC gene have been described as causing Gitelman syndrome, including
nonsense,
frameshift,
splice site and
missense mutations. Two different types of mutations exist within the group of missense mutations causing loss of NCC function. Type I mutations cause a complete loss of NCC function, in which the synthesized protein is not properly glycosylated. NCC protein harboring type I mutations is retained in the endoplasmic reticulum and cannot be trafficked to the cell surface.[13] Type II mutations cause a partial loss of NCC function in which the cotransporter is trafficked to the cell surface but has an impaired insertion in the plasma membrane. NCC harboring type II mutations have normal kinetic properties but are present in lower amounts at the cell surface, resulting in a decreased uptake of sodium and chloride.[14] NCC harboring type II mutations is still under control of its modulators and can still increase or decrease its activity in response to stimuli, whereas type I mutations cause a complete loss of function and regulation of the cotransporter.[15] However, in some patients with Gitelman's syndrome, no mutations in the NCC gene have been found despite extensive genetic work-up.
Hypertension and blood pressure
NCC has also been implicated to play a role in control of
blood pressure in the open population, with both common polymorphisms and rare mutations altering NCC function, renal salt reabsorption and, presumably, blood pressure. Individuals with rare mutations in genes responsible for salt control in the kidney, including NCC, have been found to have a lower blood pressure than
controls.[16] NCC harboring these mutations has a lower function than
wild-type cotransporter although some mutations found in individuals in the open population seem to be less deleterious to cotransporter function than mutations in individuals with Gitelman's syndrome.[15]
Furthermore, heterozygous
carriers of mutations causing Gitelman syndrome (i.e. individuals who have a mutation in one of the two
alleles and do not have the disease) have a lower blood pressure than non-carriers in the same family.[17]
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^
abMastroianni N, De Fusco M, Zollo M, Arrigo G, Zuffardi O, Bettinelli A, Ballabio A, Casari G (August 1996). "Molecular cloning, expression pattern, and chromosomal localization of the human Na-Cl thiazide-sensitive cotransporter (SLC12A3)". Genomics. 35 (3): 486–93.
doi:
10.1006/geno.1996.0388.
PMID8812482.
^Sabath E, Meade P, Berkman J, de los Heros P, Moreno E, Bobadilla NA, Vázquez N, Ellison DH, Gamba G (2004). "Pathophysiology of functional mutations of the thiazide-sensitive Na-Cl cotransporter in Gitelman disease". Am J Physiol Renal Physiol. 287 (2): F195–F203.
doi:
10.1152/ajprenal.00044.2004.
PMID15068971.
^
abAcuña R, Martínez de la Maza L, Ponce-Coria J, Vázquez N, Ortal-Vite P, Pacheco-Alvarez D, Bobadilla NA, Gamba G (2009). "Rare mutations in SLC12A1 and SLC12A3 protect against hypertension by reducing the activity of renal salt cotransporters". Journal of Hypertension. 29 (3): 475–83.
doi:
10.1097/HJH.0b013e328341d0fd.
PMID21157372.
S2CID205630437.
^Fava C, Montagnana M, Rosberg L, Burri P, Almgren P, Jönsson A, Wanby P, Lippi G, Minuz P, Hulthèn G, Aurell M, Melander O (2008). "Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure". Hum. Mol. Genet. 17 (3): 413–18.
doi:
10.1093/hmg/ddm318.
PMID17981812.
Further reading
Kamdem LK, Hamilton L, Cheng C, et al. (2008). "Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia". Pharmacogenet. Genomics. 18 (6): 507–14.
doi:
10.1097/FPC.0b013e3282fc5801.
PMID18496130.
S2CID1251203.
Coto E, Arriba G, GarcÃa-Castro M, et al. (2009). "Clinical and analytical findings in Gitelman's syndrome associated with homozygosity for the c.1925 G>A SLC12A3 mutation". Am. J. Nephrol. 30 (3): 218–21.
doi:
10.1159/000218104.
PMID19420906.
S2CID41050205.
Yasujima M, Tsutaya S (2009). "[Mutational analysis of a thiazide-sensitive Na-Cl cotransporter (SLC12A3) gene in a Japanese population—the Iwaki Health Promotion Project]". Rinsho Byori. 57 (4): 391–6.
PMID19489442.
Shao L, Liu L, Miao Z, et al. (2008). "A novel SLC12A3 splicing mutation skipping of two exons and preliminary screening for alternative splice variants in human kidney". Am. J. Nephrol. 28 (6): 900–7.
doi:
10.1159/000141932.
PMID18580052.
S2CID19321638.
Qin L, Shao L, Ren H, et al. (2009). "Identification of five novel variants in the thiazide-sensitive NaCl co-transporter gene in Chinese patients with Gitelman syndrome". Nephrology (Carlton). 14 (1): 52–8.
doi:
10.1111/j.1440-1797.2008.01042.x.
PMID19207868.
S2CID38008467.
Richardson C, Rafiqi FH, Karlsson HK, et al. (2008). "Activation of the thiazide-sensitive Na+-Cl− cotransporter by the WNK-regulated kinases SPAK and OSR1". J. Cell Sci. 121 (Pt 5): 675–84.
doi:
10.1242/jcs.025312.
PMID18270262.
S2CID33009059.
Wang XF, Lin RY, Wang SZ, et al. (2008). "Association study of variants in two ion-channel genes (TSC and CLCNKB) and hypertension in two ethnic groups in Northwest China". Clin. Chim. Acta. 388 (1–2): 95–8.
doi:
10.1016/j.cca.2007.10.017.
PMID17997379.
Zhan YY, Jiang X, Lin G, et al. (2007). "[Association of thiazide-sensitive Na+-Cl* cotransporter gene polymorphisms with the risk of essential hypertension]". Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 24 (6): 703–5.
PMID18067089.